Promoting Transparency in Veterinary Pharmaceuticals
Paws Over Profits
After watching our dogs suffer deadly side effects from Librela (Beransa), a new genetically engineered monoclonal antibody (bedinvetmab) for canine osteoarthritis, we founded Paws Over Profits to help raise awareness of the potential adverse reactions to this and other veterinary pharmaceutical drugs, treatments, products, and procedures.
WARNING:
As of September 17, 2024, statistical data from a team of scientists has indicated that one in every 110 dogs may suffer serious adverse reactions from Librela (Beransa) based on reported AERs (which reflect only a small fraction of actual cases).
Source: Librela SADRs